Abstract 1869P
Background
Despite the plethora of patient (pt) communication studies in the past decade, many of them include a diverse and heterogeneous pt and physician cohort. Thus, this single-centre prospective study aimed to measure gastrointestinal (GI) cancer pts' understanding of the information discussed during their first medical oncology visit and their satisfaction with the communication from subspecialized GI medical oncologists.
Methods
Between January and August 2021, chemotherapy-naïve pts in the gastrointestinal clinic at the Princess Margaret Cancer Centre (PMCC), Toronto, Canada, were consecutively approached within 24 hours of their initial consultation to complete a paper-based questionnaire about their understanding of their cancer (diagnosis, treatment plan/intent, prognosis) and satisfaction with the communication. GI medical oncologists concurrently completed a similar questionnaire. Pt and physician responses were compared to assess the degree of concordance. Uni/multivariable analyses were performed to identify pt/physician-based factors associated with concordance levels and pt satisfaction.
Results
A total of 184 matched pt-physician surveys were completed. The concordance rates for understanding of diagnosis, treatment plan, treatment intent, and prognosis were 92.9%, 59.2%, 66.8%, and 59.8%, respectively. Pts who reported treatment intent to be unclear at the time of the consultation were independently associated with lower satisfaction scores compared to those who reported their treatment intent to be curative (p=0.014). There was no statistical significance between patient satisfaction and whether prognosis was disclosed (p=0.08). Table: 1869P
N=184 | Fully concordant, n (%) | Partially concordant, n (%) | Fully discordant, n (%) | Missing, n (%) |
Diagnosis | 171 (92.9) | N/A | 10 (5.4) | 3 (1.6) |
Treatment Plan | 109 (59.2) | 75 (40.8) | 0 (0.0) | 0 (0.0) |
Treatment Intent | 123 (66.8) | N/A | 55 (29.9) | 6 (3.3) |
Prognosis | 110 (59.8) | N/A | 65 (35.3) | 9 (4.9) |
Conclusions
Pt understanding of treatment intent and prognosis after the first medical oncology consultation remain low. Further studies on the effectiveness of consultation aids in this setting are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Princess Margaret Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05